^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:gefitinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The NCCN NSCLC Panel recommends erlotinib and gefitinib as first-line therapy options in patients with metastatic nonsquamous NSCLC who have known active sensitizing EGFR mutation...The most commonly described mutations in EGFR (exon 19 deletions, p.L858R point mutation in exon 21) are associated with responsiveness to EGFR tyrosine kinase inhibitor (TKI) therapy...
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Excerpt:
    Gefitinib Mylan is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non‑small cell lung cancer (NSCLC) with activating mutations of EGFR‑TK.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation

    Excerpt:
    ...- Centrally confirmed EGFR exon 19 deletion (del19) or exon 21 mutation (L858R)...
    Trial ID:
    Geber
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB

    Excerpt:
    ...Patients with histologically or cytologically confirmed non-squamous non-small-cell lung cancer (NSCLC) stage II, IIIA and IIIB detected preoperatively by adequate methods and activating EGFR mutation in exons 18-21 and deemed to be able to undergo curative surgery after induction therapy....
    Trial ID:
    NeoIntercal
    More C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ESMO 2018
    Title:

    Gefitinib with or without pemetrexed in nonsquamous (NS) non-small cell lung cancer (NSCLC) with EGFR mutation (mut): Final overall survival (OS) results from a randomized phase II study

    Excerpt:
    Combination of P+G demonstrated numerically higher OS compared with G alone in tx-naïve pts with EGFR-mut advanced NS NSCLC. PFS was significantly prolonged with P+G and more pts experienced AEs in P+G vs G arm.
    Secondary therapy:
    pemetrexed
    DOI:
    https://doi.org/10.1093/annonc/mdy292.004
    Trial ID:
    NCT01469000